BiotechTube
Lykos Therapeutics

Lykos Therapeutics

San Jose, United States· Est.
lykospbc.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $200M

Overview

Lykos Therapeutics is a clinical-stage biotech company pioneering the development of MDMA-assisted therapy for PTSD, positioning it as a potential first-in-class treatment in the psychedelics sector. Operating as a public benefit corporation, the company balances therapeutic development with a stated commitment to social impact. Its lead program has completed Phase 3 trials and is under FDA review, representing one of the most advanced psychedelic drug development programs globally. The company is also exploring broader applications of its therapeutic model for other mental health conditions.

PsychiatryMental HealthPost-Traumatic Stress Disorder

Technology Platform

Integrated psychedelic-assisted therapy model combining investigational MDMA administration with a manualized protocol of preparatory and integrative psychotherapy sessions delivered by trained clinicians.

Funding History

2
Total raised:$200M
Venture$100M
Series A$100M

Opportunities

FDA approval of MDMA-assisted therapy for PTSD would create a first-in-class treatment for a condition with high unmet need, validating the psychedelic-assisted therapy model and positioning Lykos as a sector leader.
The company's public benefit corporation structure aligns with growing stakeholder demand for socially responsible business, potentially facilitating partnerships and building trust with patients and therapists.

Risk Factors

The lead program faces significant regulatory risk from the ongoing FDA review, which could result in delays, requests for additional data, or a non-approval.
Commercialization is complex, requiring the establishment of a specialized treatment delivery system, securing payer reimbursement, and overcoming potential stigma associated with psychedelic substances.

Competitive Landscape

Lykos is the current leader in the development of MDMA-assisted therapy, but faces competition from other companies developing psychedelic (e.g., psilocybin, DMT) and non-psychedelic novel therapies for PTSD and treatment-resistant depression. The competitive landscape also includes digital therapeutics and established pharmaceutical products, though Lykos's drug-therapy combination represents a distinct modality.

More companies in Neuroscience & CNS →More companies in United States →